DelveInsight’s “Thyroid Eye Disease (TED) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Thyroid eye disease (TED) or Graves’ Orbitopathy (GO) or Ophthalmopathy is an autoimmune disorder. The condition occurs when the same antibody causes thyroid dysfunction, which activates the receptors in the thyroid gland resulting in hyperthyroidism. This affects the eyes causing the inflammation of the eye tissues.
The Thyroid Eye Disease market report provides current treatment practices, emerging drugs, Thyroid Eye Disease (TED) market share of the individual therapies, current and forecasted Thyroid Eye Disease (TED) market Size
For the study period: 2017 to 2030
Segmented by geographies: 7MM
Thyroid Eye Disease Epidemiology
TED has a higher prevalence in women than men (16 per 100,000 vs. 3 per 100,000, respectively). Both men and women demonstrate a bimodal pattern of the age of diagnosis (40–44 and 60–64 years in women; 45–49 and 65–69 years in men).
The section provides insights into historical and current Thyroid Eye Disease (TED) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Thyroid Eye Disease Epidemiology Segmentation
Thyroid Eye Disease Treatment Market
Treatment for thyroid eye disease generally occurs in two phases. The first phase involves treating active eye disease. This active period usually lasts two to three years and requires careful monitoring until stable.
Some treatments include medication (local therapy, antioxidant therapy, immunomodulatory therapy), and surgery (thyroidectomy and thyroid ablation). Additionally, thyroid eye disease treatment market also includes Rehabilitative (extraocular muscle or eyelid) surgery. Correction of both hyper‐ and hypothyroidism is crucial for the ophthalmopathy. Antithyroid drugs and thyroidectomy do not influence the course of the ophthalmopathy, whereas radioiodine treatment may cause the progression of pre‐existing ophthalmopathy, especially in smokers. Glucocorticoids, however, do help in preventing in exacerbation.
Click to know more.
The Report also covers current Thyroid Eye Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Request for sample pages
Thyroid Eye Disease (TED) Market
The dynamics of the Thyroid eye disease market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period [2019‐2028]. Therapies such as RVT‐1401 (Immunovant Sciences), Teprotumumab (Horizon Therapeutics), and others are expected to enter the Thyroid Eye Disease market.
Pharma companies such as Horizon therapeutics, Immunovant Sciences, and others are working to change the dynamics of the Thyroid eye disease market is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period [2019‐2030].
Report Key Highlights
Table of Contents
*The table of contents is not exhaustive; will be provided in the final report
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Browse through our vast repository from here.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Vinita Rakheja Email: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 Country: United StatesWebsite: www.delveinsight.com/